Christoph Wanner
YOU?
Author Swipe
View article: Predictive Performance of the Cardiovascular Event Risk Test 2 Risk Score in Hemodialysis Patients with ESKD
Predictive Performance of the Cardiovascular Event Risk Test 2 Risk Score in Hemodialysis Patients with ESKD Open
Key Points The Cardiovascular Event Risk Test 2 (CERT2) risk score effectively stratified patients undergoing hemodialysis patients on the basis of their risk of major adverse cardiovascular (CV) event, CV death, and all-cause death. Patie…
View article: Protein carbamylation is associated with increased mortality and CKD progression in patients with CKD: results from the EQUAL study
Protein carbamylation is associated with increased mortality and CKD progression in patients with CKD: results from the EQUAL study Open
Background and hypothesis Urea accumulated in CKD patients’ blood can spontaneously decompose into reactive isocyanate and bind to plasma proteins in a reaction called carbamylation. Recent studies suggest a direct link between protein car…
View article: Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study
Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study Open
Background Finerenone improves cardiovascular and renal outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), but real-world data are limited. The FINE-REAL study (NCT05348733) is examining the use of finerenone…
View article: #1318 Burden of pruritus in older CKD stage 4-5 patients: 7-year follow-up of the EQUAL study
#1318 Burden of pruritus in older CKD stage 4-5 patients: 7-year follow-up of the EQUAL study Open
Background and Aims Chronic kidney disease-associated pruritus (CKD-aP) is ranked within the top 10 most prevalent and burdensome symptoms in patients with kidney failure. CKD-aP is associated with reduced quality of life (QoL), psychologi…
View article: Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from <scp>EMPEROR</scp> ‐Reduced
Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from <span>EMPEROR</span> ‐Reduced Open
Aims Empagliflozin reduces cardiovascular death (CVD) or hospitalization for heart failure (HHF), slows estimated glomerular filtration rate (eGFR) decline and improves quality of life (QoL) in heart failure with reduced ejection fraction …
View article: Impact of Improved Diagnosis and Treatment on Holistic CKD Burden
Impact of Improved Diagnosis and Treatment on Holistic CKD Burden Open
Differences in projected impacts between countries are multifactorial, though they are sensitive to demographics and health care systems. Implementation of policies that lead to improved detection and treatment of CKD are urgently required…
View article: Predicting Hospitalization and Related Outcomes in Advanced Chronic Kidney Disease: A Systematic Review, External Validation, and Development Study
Predicting Hospitalization and Related Outcomes in Advanced Chronic Kidney Disease: A Systematic Review, External Validation, and Development Study Open
Hospitalizations are important but difficult to predict for patients with advanced CKD. An improved prediction model should be developed, for example, using a more specific outcome (eg, cardiovascular hospitalizations) and more predictors …
View article: Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme
Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme Open
Background and Aims No tools are available for identifying patients with chronic kidney disease and Type 2 diabetes at high risk of hyperkalaemia. Using the FIDELITY pooled patient data set, a risk model for incident hyperkalaemia was deve…
View article: Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression
Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression Open
Key Points Acute effects impact the clinical endpoint independently of treatment effects on the chronic slope. Our findings support the 3-year total slope as the primary slope-based outcome in randomized trials. Background Slope of the GFR…
View article: Maintaining kidney health in aging societies: a JSN and ERA call to action
Maintaining kidney health in aging societies: a JSN and ERA call to action Open
Chronic kidney disease (CKD) is the fastest growing cause of death, expected to become the fifth global cause of death and the third in some countries with long life expectancy, such as Japan and Spain, by 2050. This reflects societal agin…
View article: ABCDE to identify and prevent chronic kidney disease: a call to action
ABCDE to identify and prevent chronic kidney disease: a call to action Open
Kidney disease is a global health priority affecting >850 million people worldwide. This number is projected to increase over the coming decades given the increasing prevalence of diabetes, hypertension and obesity and the aging populat…
View article: Cardiometabolic protein expression levels and pathways associated with kidney function decline in older European adults with advanced kidney disease
Cardiometabolic protein expression levels and pathways associated with kidney function decline in older European adults with advanced kidney disease Open
Background Cardiovascular disease and chronic kidney disease (CKD) progression pathophysiology are similar. We investigated associations of cardiometabolic protein expression and pathways with kidney function decline in older adults with a…
View article: Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease
Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease Open
Background Several clinical trials have shown beneficial effects of sodium–glucose co-transporter 2 (SGLT2) inhibitors on kidney disease progression and cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) w…
View article: Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial Open
Background and Aims Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time…
View article: The role of the intestinal microbiome in cognitive decline in patients with kidney disease
The role of the intestinal microbiome in cognitive decline in patients with kidney disease Open
Cognitive decline is frequently seen in patients with chronic kidney disease (CKD). The causes of cognitive decline in these patients are likely to be multifactorial, including vascular disease, uraemic toxins, blood–brain barrier leakage,…
View article: Chemotherapy-related cognitive impairment and kidney dysfunction
Chemotherapy-related cognitive impairment and kidney dysfunction Open
Cancer and kidney diseases (KD) intersect in many ways resulting in worse outcomes. Both conditions are correlated with cognitive impairment, which can be exacerbated in cancer patients by known effects of many antineoplastic drugs on cogn…
View article: Cognitive impairment in chronic kidney disease: role of brain imaging, functional imaging, electroencephalography, cerebrospinal fluid biomarkers and sensors
Cognitive impairment in chronic kidney disease: role of brain imaging, functional imaging, electroencephalography, cerebrospinal fluid biomarkers and sensors Open
Chronic kidney disease is associated with cognitive impairment although the underlying mechanisms are still not fully understood. Characterization and efficient monitoring of the cognitive impact of kidney disease and ensuing therapies are…
View article: Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD using US nationwide real-world data
Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD using US nationwide real-world data Open
Risk prediction models to identify individuals with non-diabetic CKD at high risk of adverse cardiorenal outcomes have been developed using routinely collected data from a US healthcare claims database. The models may have potential for br…
View article: Automated electronic health record-based screening for Fabry disease in unexplained left ventricular hypertrophy (FAPREV-HCM)
Automated electronic health record-based screening for Fabry disease in unexplained left ventricular hypertrophy (FAPREV-HCM) Open
Background and aims Hypertrophic cardiomyopathy (HCM) has various aetiologies, including genetic conditions like Fabry disease (FD), a lysosomal storage disorder. FD prevalence in high-risk HCM populations ranges from 0.3% to 11.8%. Early …
View article: Association of Serum Afamin Concentrations With Kidney Failure in Patients With CKD: Findings From the German CKD Cohort Study
Association of Serum Afamin Concentrations With Kidney Failure in Patients With CKD: Findings From the German CKD Cohort Study Open
Higher serum afamin concentrations appear to be associated with a higher eGFR, less albuminuria, and a lower risk for future kidney failure in patients with CKD.
View article: The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial Open
Patients with chronic kidney disease (CKD) are at risk of progressive loss of kidney function, heart failure, and cardiovascular death despite current proven therapies, including renin-angiotensin system inhibitors (RASi), sodium glucose c…
View article: Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis
Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis Open
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASC…